Expert Interview
Discussing Alnylam’s Lumasiran in primary hyperoxaluria type 1
Ticker(s): ALNYA nephrologist with experience in treating PH1
Please describe your clinical practice. How many patients with PH1 do you see on a yearly basis? What is the standard of care, and how well do patients respond to it?
Can you please walk us through the rationale behind targeting hydroxyacid oxidase 1 HAO1 as a pathway to treat PH1?
Added By: slingshot_insightsCould you please discuss the results of Lumasiran in reducing plasma oxalate POx? 33% and 42% mean reductions in POx from baseline to Month 6. Treatment with lumasiran led to 35 micromol/L and 48 micromol/L mean absolute reductions in POx from baseline to Month 6.
Added By: slingshot_insightsCould you comment on the separate analysis presented at ERA-EDTA?
Can you tell us more about the RNAi asset nedosiran, considering its mixed bag of data in PH3, but approval for PH1 since 2019? How does Lumasiran compare to Dicerna's (DRNA) Nedosiran? How well do patients respond to Nedosiran, is there an unmet need still for PH1 patients, and do you think Lumasiran can fill the gap?
How likely are you to switch patients to Lumasiran?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
